The popularity of Viagra initially fueled a boom for major pharmaceutical companies, but recent changes present a uncertain outlook for investors. Off-patent competitors are eating into profits, and continued legal battles add additional complexity to the landscape. While specific companies may still see gains from adjacent services, the general… Read More